US pharma major Merck (NYSE: MRK) has reported a Phase III success for Welireg (belzutifan) plus Keytruda (pembrolizumab) as ...

Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to ...

Sepsis, a common complication following burns, trauma, and major surgery, remains the leading cause of death among critically ill patients. Globally, there are about 48.9 million sepsis patients and ...

Resolutions adopted by the World Health Assembly represent the highest level of political commitment in global health. Endorsed by Ministers of Health from WHO Member States, these resolutions signal ...

The theme of this year’s conference is “Supporting you every step of the way: from diagnosis to transplant.” Kidney Action Week is a highlight of Kidney Month, with four days of educational sessions ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when ...

Telix reported FY2025 revenue of $804M, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing $622M. Read why TLX stock is a Buy.

The third and final day of the 2026 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium highlighted important developments in kidney cancer treatment, including combination ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

March is National Kidney Month, a time to shine a light on the thousands of individuals whose lives are deeply affected by ...

SAN FRANCISCO -- The adjuvant combination of pembrolizumab (Keytruda) and belzutifan (Welireg) significantly improved disease ...